American College of Clinical Pharmacy
      Search      Cart
         

SOTSAP 2024


Member Price:
$88.00
Nonmember Price:
$132.00
ASHP members, please call (913)492-3311 to recieve member pricing. Your ASHP membership number and expiration date are required.

ACCP’s Self-Assessment Programs are home study series that provide clinical pharmacists with pertinent therapeutic updates to enhance their practice skills and improve patient outcomes.

The first release in ACCP’s Solid Organ Transplantation Self-Assessment Program (SOTSAP) features comprehensive reviews, timely updates, and case series on various topics relating to the solid organ transplant population. The target audience for SOTSAP 2024 is board-certified and advanced-level clinical pharmacists who provide care to solid organ transplant candidates and recipients.

Lyndsey J. Bowman
Lyndsey J. Bowman

The book contains 10 chapters with a total available 36.5 continuing pharmacy education (CPE) credits. The content of SOTSAP 2024 was developed under the leadership of Faculty Panel Chair Lyndsey J. Bowman, Pharm.D., FCCP, FAST, BCPS, BCTXP.

The book consists of four topic sections. The first section, Immunosuppression Management/Monitoring, includes three chapters that address drug development and novel immunomodulatory agents in solid organ transplant, and offer information and updates in outcome measures, biomarkers, and antibody-mediated rejection. The second section, Disease State Management, includes three chapters that provide updates in cytomegalovirus, peri-transplant antithrombotic management, and a comprehensive approach to addressing gastrointestinal complications post-transplant. The third section, Practice Management, includes two chapters that cover practice management strategies for optimizing transplant evaluation and vaccination practices. The fourth section, Case Series, includes two features that detail the post-transplant management of anemia and neutropenia.

Each SOTSAP release has continuing education activities that cover the most recent published data (past 3–5 years) on a specific therapeutic area or patient-care problem. This content is provided as an electronic book (interactive PDF) with high-level updates designed, as appropriate to the topic, in three formats:

  • Traditional review-style chapters
  • Case series (major sections of learning content bookended by a sample case and its explained answer)
  • Recorded webcast (PowerPoint presentation; includes PDF of the transcribed narrative)

SOTSAP chapters and features are fully referenced, with clickable hyperlinks to literature compilers such as PubMed. Other links provide ready access to clinical practice guidelines, official recommendations, and patient assessment tools. Graphics focus on pivotal studies, patient care scenarios, and take-home points that can be readily integrated into clinical practice. 

Release Date: November 15, 2024
BCTXP Deadline: November 14, 2025
ACPE Deadline: November 15, 2027

ISBN: 978-1-964074-13-9
Publication Year: 2024
Format: PDF and ePub

Contents

SOTSAP 2024, Chapter 1: Updates in Transplant Outcome Measures and Biomarkers

Care of solid organ transplantation (SOT) recipients has improved remarkably over the past 50 years, and transplantation offers a clear survival benefit and higher quality of life while lowering health care costs (Lentine 2024; Sussell 2020; Axelrod 2018; Wolfe 1999). As a result, transplantation is the preferred treatment for end-stage organ failure. However, despite these successes, SOT recipients often face many complications that contribute to morbidity and mortality (Van Loon 2020; Legendre 2014). For example, 10-year all-cause graft failure after kidney transplantation remains high at around 50%. This number corresponds to many kidney recipients requiring a second or third transplant, whereas for others, it represents premature death
from cardiovascular disease, infection, or malignancy (Lentine 2024; Lamb 2011). Statistics are similar for non-kidney transplant recipients as well.

SOTSAP 2024, Chapter 2: Transplant Drug Development and Novel Immunomodulatory Agents

Short- and long-term allograft survival after solid organ transplantation is intricately linked to the efficacy of immunosuppressive regimens, infection prophylaxis, and medication adherence. Extraordinary advances in desensitization, induction and maintenance immunosuppression, and rejection therapies have occurred over the past 70 years since the first successful kidney transplant in 1954. The advent of highly effective maintenance immunosuppressive therapy in the 1980s and 1990s significantly reduced rejection rates and risk of mortality and graft failure within the first year after transplantation. The calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, were FDA approved in 1983 and 1994, respectively, for the prevention of acute cellular rejection (ACR) after transplantation. To date, CNIs remain the backbone of most modern immunosuppressive
regimens.

SOTSAP 2024, Chapter 3: Diagnosis and Treatment of Antibody-Mediated Rejection

Antibody-mediated rejection (AMR) is a significant contributor to allograft dysfunction and loss among solid organ transplant recipients. Identifying the true incidence of AMR among each organ group is challenging, primarily because of the evolving nature of its definition and diagnostic criteria over the years. However, as our understanding of immunobiology advances and we implement improved immunosuppressive methods alongside more refined donor and recipient matching techniques, there has been a notable decrease in the rates of AMR within the first year posttransplant (Good-Weber 2020).

SOTSAP 2024, Chapter 4: Updates in Cytomegalovirus Management

Cytomegalovirus (CMV) is a ubiquitous beta herpesvirus that causes a primary infection, typically in childhood, that is followed by lifelong latency. In immunocompetent hosts, the virus causes a mild constellation of upper respiratory tract symptoms at most and is often completely asymptomatic. However, in immunocompromised patients, it can have significant sequelae. For the treatment of CMV, historically known as the “troll of transplantation” because of its severe manifestations and association with patient morbidity, graft loss, and mortality (Balfour 1979), the development of ganciclovir and later its oral prodrug, valganciclovir, improved early outcomes. However, despite the development of these potent antiviral agents, CMV infection after solid organ transplantation continues to affect graft outcomes (Leeaphorn 2019). This is likely attributable to a lack of pretransplant host immunity and an allograft with viral inclusion at transplantation that later, because of some unknown trigger, reactivates, resulting in primary infection.

SOTSAP 2024, Chapter 5: GI Complications After Solid Organ Transplantation

The most commonly reported GI complication after transplantation is diarrhea (39%–50%), but indigestion/reflux (33%–91%), abdominal pain (25%–73%), nausea (24%–27%), vomiting (17%–20%), and constipation (19%–60%) are also commonly reported (Jokinen 2010; Gil-Vernet 2007; Herrero 2007). Solid organ transplant recipients have many etiologies for diarrhea similar to nontransplant recipients, but they are at increased risk of additional GI complications because of transplant medications, opportunistic infections, and other disease states that can present during or recur after transplantation. The frequency of these complications has been shown to affect quality of life as well as lead to weight loss, medication toxicity, and increased hospital admissions (Tielemans 2019; Jokinen 2010).

SOTSAP 2024, Chapter 6: Peritransplant Antithrombotic Management

Across solid organ transplantation, patients commonly present for evaluation or transplantation with indications for oral or parenteral anticoagulation and/or antiplatelet therapy. The presence of these agents poses a significant bleeding risk at the time of transplantation, so in most cases, these agents will need to be thoughtfully managed from the time of listing to the date of transplantation. A thorough understanding of the strength of guideline-based recommendations and their associated evidence level for antithrombotic medications, risk of short-term thrombosis if discontinued, usefulness of periprocedural bridging, agents available for urgent reversal, and an understanding of proper reinitiation after transplantation are critical for the transplant pharmacist. This chapter guides the transplant pharmacist through these considerations with an eye toward identifying appropriate management options on the basis of patient- and surgery-specific characteristics.

SOTSAP 2024, Chapter 7: Transplant Evaluation Optimization

The transplant pharmacist plays an integral role in evaluating the suitability of candidates for solid organ transplantation. Pharmacists are uniquely qualified to assess both pharmacologic and nonpharmacologic risks in patients being evaluated for transplantation. They work closely with the multidisciplinary team to determine suitability for transplantation and mitigate risks before transplantation. Proper screening and evaluation by a transplant pharmacist can improve posttransplant outcomes.

SOTSAP 2024, Chapter 8: Pre- and Posttransplant Vaccination

Vaccines have revolutionized medicine by reducing, eliminating, and in some cases eradicating select infectious diseases. In addition to what they offer the individual, they safeguard the public health. Today, vaccines are available to help protect against more than 20 diseases (WHO 2024).

SOTSAP 2024, Chapter 9: Case Series: Anemia Post-Solid Organ Transplant

Post-transplant anemia is a common sequela of solid organ transplant (SOT) that is often underrecognized. Apart from chronic kidney disease (CKD) in the pre-transplant setting, anemia in the nonrenal SOT population may or may not be related to kidney disease or kidney function (Vanrenterghem 2003). Information on outcomes in literature for nonrenal transplant recipients is limited. Assumptions on clinical management are often extrapolated from the setting of anemia of CKD (Blosser 2010). Anemia often occurs after kidney transplant and may improve over time, but may persist or worsen in some patients. Anemia post-transplant can result from the transplant procedure, adverse effects from medications, or new or preexisting comorbidities. The prevalence rate of anemia in kidney transplant recipients varies widely, ranging from 20%–60% depending on the criteria used (Imoagene-Oyedeji 2006). The prevalence of anemia is up to 50% in lung and liver transplant recipients and 78% in heart transplant recipients (Blosser 2010).

SOTSAP 2024, Chapter 10: Case Series: Management of Neutropenia

Neutropenia is a common complication after solid organ transplantation, which may increase a patient’s risk of infections, acute and chronic rejection, and allograft loss. In published transplant literature, neutropenia and leukopenia are often used interchangeably, though neutrophils are particularly critical in host defense against bacterial and fungal infections.

SOTSAP 2024, Chapter 1: Updates in Transplant Outcome Measures and Biomarkers

Faculty

Abbie D. Leino, Pharm.D., Ph.D., BCPS

Assistant Professor
Division of Translational and Clinical Pharmacology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Reviewers

Tiffany E. Kaiser, Pharm.D., MS, FCCP, AF-AASLD

Research Professor
College of Medicine, Department of Digestive Disease
University of Cincinnati
Cincinnati, Ohio

Jillian P. Casale, Pharm.D., BCTXP

Senior Transplant Pharmacist
Department of Pharmacy
Cooperman Barnabas Medical Center
Livingston, New Jersey

Kimberly Harrison, Pharm.D., BCPS, BCTXP

Cardiothoracic Transplant Clinical Specialist
Department of Pharmaceutical Services
Vanderbilt University Medical Center
Nashville, Tennessee

SOTSAP 2024, Chapter 2: Transplant Drug Development and Novel Immunomodulatory Agents

Faculty

Reviewers

Cody A. Moore, Pharm.D., MPH, BCTXP, BCPS

Clinical Pharmacist, Lung Transplant
and Advanced Lung Diseases
Department of Pharmacy
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania

Carlo J. Iasella, Pharm.D., MPH, BCTXP, BCPS

Assistant Professor
Department of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Pittsburgh, Pennsylvania

Reviewers

Jennifer Trofe-Clark, Pharm.D., FCCP, BCPS

Adjunct Professor of Surgery and
Adjunct Professor of Medicine
Divisions of Transplantation and Renal-
Electrolyte Hypertension
Associated Faculty of the Perelman School
of Medicine, University of Pennsylvania
Program Manager, Kidney-Pancreas
Transplant Clinical Research Program
Penn Transplant Institute, Hospital of
the University of Pennsylvania
Philadelphia, Pennsylvania

Ali J. Olyaei, Pharm.D., BCTXP

Professor of Medicine and Pharmacy Practice
Division of Nephrology & Hypertension
Oregon Health & Science University
Department of Pharmacy Practice
Oregon State University
Clinical Pharmacist, Kidney, Pancreas
and Liver Transplantation
Department of Pharmacy
OHSU Hospital
Portland, Oregon

Lisa Hutchinson, Pharm.D., BCTXP

Clinical Pharmacist, Abdominal Transplant
Department of Pharmacy
Ochsner Medical Center
New Orleans, Louisiana

SOTSAP 2024, Chapter 3: Diagnosis and Treatment of Antibody-Mediated Rejection

Faculty

Miae Kim, Pharm.D., M.S., BCPS

Clinical Pharmacy Specialist
Department of Cardiology
Brigham and Women’s Hospital
Boston, Massachusetts

Yanmen Yang-Liu, Pharm.D., BCPS

Ambulatory Cardiothoracic Transplant Pharmacist
Department of Pharmacy Services
Brigham and Women’s Hospital
Boston, Massachusetts

Steven Gabardi, Pharm.D., FCCP, BCPS

Medical Science Liaison
The Medical Affairs Company
Wilmington, Massachusetts

At the time of writing, Dr. Gabardi was Director of Medical Education, TG Medical Education, Wilmington, Massachusetts. His contribution to this chapter was completed before taking a new position with The Medical Affairs Company.

 

Reviewers

Ashley Anh Vo, Pharm.D., FAST

Professor of Pediatrics and Medicine
Administrative Director, Transplant Immunotherapy Program
Department of Kidney Transplant
Cedars-Sinai Medical Center
Los Angeles, California

Sandra El Hajj, Pharm.D., BCPS, BCTXP

Solid Organ Transplant Pharmacotherapy Specialist
Department of Pharmacy Services
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates

Dana Pierce, Pharm.D., BCTXP

Clinical Assistant Professor/Clinical Pharmacist
Department of Pharmacy Practice
University of Illinois Chicago
Chicago, Illinois

SOTSAP 2024, Chapter 4: Updates in Cytomegalovirus Management

Faculty

Margaret R. Jorgenson, Pharm.D., BCTXP

Clinical Pharmacist
Department of Pharmacy
UW Health
Madison, Wisconsin

Hanna L. Kleiboeker, Pharm.D., BCTXP

Clinical Pharmacist
Department of Pharmacy
UW Health
Madison, Wisconsin

Reviewers

Lindsey P. Toman, Pharm.D., BCPS, BCTXP

Clinical Pharmacy Specialist, Solid Organ Transplantation
Department of Pharmacy
The Johns Hopkins Hospital
Baltimore, Maryland

Reed Hall, Pharm.D., BCPS, BCTXP

Lead Solid Organ Transplant Clinical Pharmacy Specialist
PGY2 Solid Organ Transplant Residency Program Director
Department of Pharmacy
University Health
San Antonio, Texas
Adjoint Assistant Professor
University of Texas College of Pharmacy
Austin, Texas

SOTSAP 2024, Chapter 5: GI Complications After Solid Organ Transplantation

Faculty

Erika Meredith, Pharm.D., BCTXP

Clinical Pharmacy Specialist, Solid Organ Transplant
Department of Pharmacy
Emory University Hospital
Atlanta, Georgia

Reviewers

Jennifer I. Melaragno, Pharm.D., FCCP, BCPS

Abdominal Transplant Clinical Pharmacist
Department of Pharmacy
University of Rochester Medical Center
Rochester, New York

Helen Sweiss, Pharm.D., FAST, BCTXP

Clinical Pharmacist Specialist, Solid Organ Transplant
Department of Pharmacotherapy and Pharmacy Services
University Health, University Health Transplant Institute
San Antonio, Texas

Conner Patton, Pharm.D., MBA, BCTXP

Cardiothoracic Transplant Pharmacist
INTEGRISH Advanced Cardiac Care
INTEGRIS Health
Oklahoma City, Oklahoma

SOTSAP 2024, Chapter 6: Peritransplant Antithrombotic Management

Faculty

Ian B. Hollis, Pharm.D., FCCP, BCPS

Associate Professor
Division of Pharmacotherapy and Therapeutics
University of North Carolina Eshelman
School of Pharmacy
Clinical Specialist
Advanced Heart Failure, LVAD and Heart Transplantation
University of North Carolina Medical Center
Chapel Hill, North Carolina

Patrick M. Klem, Pharm.D., BCPS, BCTXP

Clinical Pharmacy Specialist – Solid Organ Transplant
Department of Pharmacy
UCHealth
Denver, Colorado

Reviewers

David Salerno, Pharm.D., FAST, BCTXP

Clinical Pharmacy Manager, Liver Transplantation
Department of Pharmacy
NewYork-Presbyterian Hospital/
Weill Cornell Medical Center
New York, New York

Alexandra L. Bixby, Pharm.D., BCTXP

Clinical Pharmacy Specialist – Solid Organ Transplant
Department of Pharmacy Services
University Hospitals Cleveland Medical Center
Cleveland, Ohio

SOTSAP 2024, Chapter 7: Transplant Evaluation Optimization

Faculty

Kristine S. Schonder, Pharm.D.

Associate Professor
Department of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Clinical Specialist, Transplantation
Thomas E. Starzl Transplantation Institute
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania

Katelyn Rudzik, Pharm.D., BCTXP

Clinical Pharmacy Specialist – Lung Transplantation
Department of Pharmacy
Cleveland Clinic
Cleveland, Ohio

Reviewers

Holly B. Meadows, Pharm.D., MBA, BCPS, BCTXP

Pharmacy Manager
Department of Pharmacy
CarolinaEast Health System
New Bern, North Carolina

Dawn M. Pluckrose, Pharm.D., BCTXP

Abdominal Transplant Clinical Pharmacy Specialist
Department of Pharmacy
Tufts Medical Center
Boston, Massachusetts

SOTSAP 2024, Chapter 8: Pre- and Posttransplant Vaccination

Faculty

Lisa Potter, Pharm.D., FCCP, FAST, BCTXP, BCPS

Clinical Coordinator, Transplant Pharmacy Services
Department of Pharmacy
University of Chicago Medicine
Chicago, Illinois

Reviewers

Joelle Nelson, Pharm.D., FAST, BCPS, BCTXP

Clinical Pharmacist Specialist, Solid Organ Transplant
Department of Pharmacotherapy and Pharmacy Services
University Health, University Health Transplant Institute
San Antonio, Texas

Rickey A. Evans, Pharm.D., BCTXP

Clinical Pharmacy Specialist – Lung Transplant
Department of Pharmacy Services
University of Kentucky Healthcare
Lexington, Kentucky

SOTSAP 2024, Chapter 9: Case Series: Anemia Post-Solid Organ Transplant

Faculty

David J. Quan, Pharm.D., FCCP, BCTXP, BCPS

Pharmacy Supervisor – Solid Organ Transplant
Department of Pharmaceutical Services
UCSF Health
San Francisco, California

Reviewers

Joshua J. Wiegel, Pharm.D., BCTXP, BCPS

Clinical Pharmacist
Department of Pharmacy
UW Health
Madison, Wisconsin

Kelsey Klein, Pharm.D., BCPS, BCTXP

Clinical Pharmacy Specialist, Solid Organ Transplant
Department of Pharmacotherapy and Pharmacy Services
University Health, University Health Transplant Institute
San Antonio, Texas

SOTSAP 2024, Chapter 10: Case Series: Management of Neutropenia

Faculty

Lauren Sacha, Pharm.D., BCPS, BCTXP

Transplant Unit-Based Clinical Pharmacist
Department of Pharmacy
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Reviewers

Nicole R. Alvey, Pharm.D., FAST, BCPS, BCTXP

Associate Professor of Clinical Sciences
Doctor of Pharmacy Program
Roosevelt University College of
Science, Health and Pharmacy
Schaumburg, Illinois
Clinical Pharmacy Specialist, Solid Organ Transplant
Department of Pharmacy
Rush University Medical Center
Chicago, Illinois

Alexa J. Ray, Pharm.D., BCPS, BCTXP

Transplant Clinical Pharmacist
Piedmont Transplant Institute
Piedmont Healthcare
Atlanta, Georgia

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCTXP.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Contents

SOTSAP 2024, Chapter 1: Updates in Transplant Outcome Measures and Biomarkers

Activity Number: 0217-9999-24-241-H01-P
Contact Hour(s): 5.00
Activity Type: Application Based

Learning Objectives

1. Evaluate current transplant outcome measures for managing immunosuppressive drugs and important gaps.
2. Assess the differences in the available biomarker-based monitoring strategies and analyze the limitations.
3. Evaluate the potential role of emerging technology, such as omics-based biomarkers and artificial intelligence, in future immunosuppression management.

SOTSAP 2024, Chapter 2: Transplant Drug Development and Novel Immunomodulatory Agents

Activity Number: 0217-9999-24-242-H01-P
Contact Hour(s): 4.00
Activity Type: Application Based

Learning Objectives

1. Evaluate opportunities and challenges for immunomodulatory drug development after solid organ transplantation.
2. Evaluate new roles and novel immunomodulatory agents for induction immunosuppression.
3. Assess potential new roles and novel immunomodulatory agents for maintenance immunosuppression.

SOTSAP 2024, Chapter 3: Diagnosis and Treatment of Antibody-Mediated Rejection

Activity Number: 0217-9999-24-243-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Analyze the impact of various assays on diagnosing and monitoring donor-specific antibodies to guide antibody-mediated
rejection (AMR) therapy.
2. Design a pharmacotherapy plan that considers patient-specific factors for the treatment of AMR.
3. Evaluate the current therapies used in desensitization protocols and distinguish the benefits and limitations of each
therapy.

SOTSAP 2024, Chapter 4: Updates in Cytomegalovirus Management

Activity Number: 0217-9999-24-244-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Analyze the gaps in current cytomegalovirus (CMV) guidelines as they pertain to drugs and management strategies.
2. Assess the differences, benefits, and limitations of available preventive strategies.
3. Classify available antiviral treatments and their current role(s) in therapy.
4. Evaluate the role of CMV antiviral stewardship, and formulate strategies for clinical practice integration.

SOTSAP 2024, Chapter 5: GI Complications After Solid Organ Transplantation

Activity Number: 0217-9999-24-245-H01-P
Contact Hour(s): 3.00
Activity Type: Application Based

Learning Objectives

1. Assess the risk of different immunosuppressive therapies in causing GI complications after solid organ transplantation,
and design a revised immunosuppressive regimen to alleviate these complications.
2. Analyze patient risk factors for infectious causes of GI complications, and devise a strategy to decrease patient risks.
3. Construct an appropriate treatment strategy on the basis of diagnosis for infectious GI complications.
4. Evaluate the relationship between GI complications after solid organ transplantation, the organ transplanted, and patient
implications.

SOTSAP 2024, Chapter 6: Peritransplant Antithrombotic Management

Activity Number: 0217-9999-24-246-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Classify common conditions requiring chronic anticoagulation in patients awaiting solid organ transplantation.
2. Design a management plan for patients taking oral antithrombotic medications who are listed for solid organ transplantation.
3. Construct a protocol designed to standardize the management of reversal agents in patients presenting for solid organ
transplantation while taking antithrombotic medications.
4. Evaluate the appropriate agents, doses, and timing of postoperative antithrombotic medications according to transplant-
specific indications and considerations.

SOTSAP 2024, Chapter 7: Transplant Evaluation Optimization

Activity Number: 0217-9999-24-247-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Distinguish the role of the transplant pharmacist in the pretransplant evaluation visit.
2. Evaluate a comprehensive medication review and assess a patient’s adherence status to determine suitability for
transplantation.
3. Detect nonpharmacologic factors that can affect posttransplant outcomes.
4. Assess the impact of pretransplant medications and behaviors on perioperative and posttransplant risks.

SOTSAP 2024, Chapter 8: Pre- and Posttransplant Vaccination

Activity Number: 0217-9999-24-248-H06-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Design an optimal vaccination regimen for organ transplant candidates and recipients.
2. Distinguish vaccination in organ transplant recipients from the general population, focusing on vaccine efficacy and safety.
3. Devise a strategy to complete vaccination given local policies and procedures.

SOTSAP 2024, Chapter 9: Case Series: Anemia Post-Solid Organ Transplant

Activity Number: 0217-9999-24-249-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Evaluate solid organ transplant (SOT) recipients for anemia.
2. Assess the patient for dapsone-induced adverse effects.
3. Design a management strategy for SOT recipients with human parvovirus B19 infection.
4. Distinguish the need for treatment of thrombotic microangiopathy in SOT recipients.

SOTSAP 2024, Chapter 10: Case Series: Management of Neutropenia

Activity Number: 0217-9999-24-250-H01-P
Contact Hour(s): 3.50
Activity Type: Application Based

Learning Objectives

1. Assess solid organ transplant recipients for the presence and severity of neutropenia and evidence-based risk factors.
2. Evaluate patients for telomere-related genetic polymorphisms and their significance before and after transplantation.
3. Design therapeutic regimens for the prevention and management of neutropenia.
4. Analyze the role of granulocyte colony-stimulating factor use in transplant recipients and compare the risk-benefit of their
use.

Disclosures


Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.

Documents Click on a document to view/download.

Sample Chapter
Faculty and Faculty Disclosures